Sunday, May 24, 2015

Provectus taking novel path to treat cancer

Provectus taking novel path to treat cancer

May 19, 2015 by · Leave a Comment 

Tweet Rather than taking a biochemistry approach to develop drugs that kill cancer cells, Provectus Biopharmaceuticals (NYSE MKT:PVCT) is using physical chemistry by harnessing the unique properties of Rose Bengal, a first-in-class halogenated xanthene. “We are taking a different type of molecule and a different basis for the mechanism of action than has been used […]

Relmada gets U.S. patent allowance for SECUREL

Relmada gets U.S. patent allowance for SECUREL

May 12, 2015 by · Leave a Comment 

Tweet Relmada Therapeutics (OTCQB:RLMD) has received a notice of allowance from the U.S. patent office for its proprietary SECUREL abuse deterrent technology platform. The new SECUREL patent application is entitled, “Multimodal Abuse Resistant and Extended Release Opioid Formulations.” Once granted, the patent is expected to be valid until at least 2028. Relmada’s lead development program, […]

TransEnterix readying FDA filing of SurgiBot in mid-year

TransEnterix readying FDA filing of SurgiBot in mid-year

April 28, 2015 by · Leave a Comment 

http://www.youtube.com/watch?v=L6Bbk1MvHN0′]

Tweet TransEnterix (NYSE MKT:TRXC) plans to file for FDA approval in mid-year of its SurgiBot robotic platform to enhance minimally invasive laparoscopic surgery through a single surgical incision. “We anticipate a six-to-nine month review cycle for our 510(k) submission and hope to launch in the first half of 2016,” CEO, Todd Pope, says in an […]

HCW starts Stemline Therapeutics at buy

HCW starts Stemline Therapeutics at buy

April 27, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Stemline Therapeutics (NASDAQ:STML) with a “buy” rating and a 12-month price target of $38. The stock closed at $16.58 on Friday. Stemline is focused on the development of novel anti-cancer therapeutics that eradicate both the tumor bulk and cancer stem cells (CSCs). “Stemline represents a unique investment opportunity […]

In conversation with Dr. Isaac Ciechanover

In conversation with Dr. Isaac Ciechanover

March 31, 2015 by · Leave a Comment 

Tweet As president and CEO of Atara Biotherapeutics (NASDAQ:ATRA), Dr. Isaac Ciechanover has spent the past 20 years working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He was a former partner in the life sciences practice at Kleiner Perkins Caufield & Byers and spent a decade as Celgene’s executive […]

Amarantus to start Phase 2b with eltoprazine in PD

Amarantus to start Phase 2b with eltoprazine in PD

March 26, 2015 by · Leave a Comment 

Tweet Amarantus BioScience Holdings (OTCQB:AMBS) has an active IND application with the neurology division of the FDA to start a Phase 2b program of eltoprazine for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). The company expects to initiate patient enrollment and dosing in a 60-subject clinical study in individuals with PD in the second […]

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

March 17, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. “We have multiple late-stage product candidates based on our proven hydrogel technology platform, addressing the largest […]

Ocular Therapeutix posts positive Phase 3a OTX-DP data

Ocular Therapeutix posts positive Phase 3a OTX-DP data

March 10, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) has announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (sustained release dexamethasone), for the treatment of ocular inflammation and pain following cataract surgery. The Phase 3a study, which enrolled 247 patients, met both primary efficacy […]

Relmada names clinicians, researchers to advisory roles

Relmada names clinicians, researchers to advisory roles

March 5, 2015 by · Leave a Comment 

Tweet Relmada Therapeutics (OTCQB:RLMD) has appointed several leading clinicians and researchers, with expertise in opioid receptors, addiction, psychiatry, neuropathic pain, and clinical trial methodology, to advisory roles. The panel will provide support for planning Relmada’s development programs to advance its pipeline of novel investigational therapies to treat chronic pain. “Their extensive experience and depth of […]

Synergy Disc Replacement sets global sales plan

Synergy Disc Replacement sets global sales plan

March 3, 2015 by · Leave a Comment 

Tweet After an initial market launch of its revolutionary SYNERGY DISC that exceeded expectations in Germany last year, closely-held Synergy Disc Replacement Inc. (SDRI) is planning to expand distribution aggressively in Europe, Asia Pacific and other parts of the world. “We are also in the early stages of developing our U.S. regulatory strategy to gain […]

Next Page »

Email Newsletters with Constant Contact
Google+